B6J.CBCa-Per2tm1Jt Tg(Thy1-MAPT*P301S)2541Godt/H

Status

Available to order

EMMA IDEM:15800
Citation informationRRID:IMSR_EM:15800 

Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.

 
International strain nameB6J.CBCa-Per2tm1Jt Tg(Thy1-MAPT*P301S)2541Godt/H
Alternative namemPer2Luc x B6J.CBCa-Tg(Thy1-MAPT*P301S)2541Godt/H (PER2::LUC x P301S T43)
Strain typeTransgenic Strains
Allele/Transgene symbolTg(Thy1-MAPT*P301S)2541Godt, Per2tm1Jt
Gene/Transgene symbolTg(Thy1-MAPT*P301S)2541Godt, Per2

Information from provider

ProviderNina Rzechorzek
Provider affiliationCell Biology, MRC Laboratory of Molecular Biology
Additional ownerMichel Goedert, MRC Laboratory of Molecular Biology, UK. Joseph Takahashi, UT Southwestern Medical Center and Howard Hughes Medical Institute, US.
Genetic informationThis strain has been generated by crossing strain B6J.Cg-Tg(Thy1-MAPT*P301S)2541Godt/H (EM:15269) with a strain containg the allele Per2 allele (Per2tm1Jt MGI :3040876) .
Phenotypic informationHomozygous:
Homozygous for human 0N4R P301S Tau (MAPT) transgene Progressive impaired gait culminating in hindlimb paralysis around 7-8 months of age. Homozygous for mPer2Luc transgene - no phenotype

Heterozygous:
Heterozygous for human 0N4R P301S Tau (MAPT) transgene Same as for homozygous mice but delayed and with a wider window. Heterozygous mice usually reach end point between 12 and 20 months of age. Heterozygous for mPer2Luc transgene - no phenotype
Breeding historyMore than 10 backcrosses onto C57BL/6J background.
ReferencesNone available
Homozygous fertileyes
Homozygous viableyes
Homozygous matings requiredno
Immunocompromisednot known

Information from EMMA

Archiving centreMary Lyon Centre at MRC Harwell, Oxford, United Kingdom

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

IMPC phenotypes (gene matching)
  • increased lean body mass / IMPC
  • increased circulating alkaline phosphatase level / IMPC
  • abnormal coat/hair pigmentation / IMPC
  • abnormal behavior / IMPC
MGI phenotypes (gene matching)
  • salivary gland epithelial hyperplasia / MGI
  • abnormal body weight / MGI
  • increased body weight / MGI
  • abnormal retina morphology / MGI
  • pup cannibalization / MGI
  • abnormal food preference / MGI
  • abnormal sleep pattern / MGI
  • abnormal blood vessel morphology / MGI
  • increased mortality induced by gamma-irradiation / MGI
  • reduced female fertility / MGI
  • decreased litter size / MGI
  • premature death / MGI
  • no abnormal phenotype detected / MGI
  • abnormal bone marrow cell morphology/development / MGI
  • abnormal male preputial gland morphology / MGI
  • abnormal retinal vasculature morphology / MGI
  • no phenotypic analysis / MGI
  • decreased cellular sensitivity to gamma-irradiation / MGI
  • nervous system phenotype / MGI
  • abnormal nervous system morphology / MGI
  • increased incidence of tumors by ionizing radiation induction / MGI
  • increased hematopoietic stem cell number / MGI
  • abnormal brain wave pattern / MGI
  • improved glucose tolerance / MGI
  • behavior/neurological phenotype / MGI
  • abnormal food intake / MGI
  • abnormal maternal behavior / MGI
  • abnormal basal metabolism / MGI
  • early reproductive senescence / MGI
  • prolonged estrous cycle / MGI
  • absent estrous cycle / MGI
  • abnormal pregnancy / MGI
  • enhanced conditioned place preference behavior / MGI
  • enhanced behavioral response to cocaine / MGI
  • increased salivary gland tumor incidence / MGI
  • abnormal hematopoietic stem cell physiology / MGI
  • increased bone volume / MGI
  • abnormal circadian temperature homeostasis / MGI
  • decreased hematopoietic stem cell proliferation / MGI
  • increased lymphoma incidence / MGI
  • increased bone ossification / MGI
  • abnormal circadian behavior / MGI
  • shortened circadian behavior period / MGI
  • arrhythmic circadian behavior persistence / MGI
  • delayed circadian behavior phase / MGI
  • abnormal locomotor circadian rhythm / MGI
  • abnormal circadian sleep/wake cycle / MGI

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
MTA will be issued after an order has been submitted.

EMMA conditions
Legally binding conditions for the transfer

Right strain for your research?

The information provided on this page is, to the best of EMMA’s knowledge, based on data supplied by the original provider. End users are responsible for reviewing these details and for validating the strain and its suitability for their experimental use.​
Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).